FDA Approves Biosimilar for Multiple Inflammatory Conditions

Article

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

Officials from the FDA have approved adalimumab-afzb (Abrilada, Pfizer) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. It is indicated to serve as a biosimilar to adalimumab (Humira). 1

The approval was based on the review of a comprehensive data package, as well as results from the REFLECTIONS B538-02 clinical comparative study. 1

REFLECTIONS B538-02 is a randomized, double blind study where the primary endpoint is an equivalent ACR20 response at Week 12 of study treatment. Patients with moderate to severe rheumatoid arthritis would take PF-06410293 in combination with methotrexate. 2

This clinical trial evaluated the efficacy, safety, and immunogenicity of adalimumab-afzb, with no clinically meaningful differences compared to the reference product. 1

Adalimumab is indicated to target and block TNF, which is presumed to help reduce inflammation. 1

Reference

  • FDA approves Pfizer’s biosimilar, Abrilada (adalimumab-afzb) for multiple inflammatory conditions [news release]. New York, NY; Pfizer: November 18, 2019. https://investors.pfizer.com/investor-news/press-release-details/2019/FDA-Approves-Pfizers-Biosimilar-ABRILADA-adalimumab-afzb-for-Multiple-Inflammatory-Conditions/default.aspx. Accessed November 18, 2019.
  • Pfizer announces positive top-line results from the comparative reflections B538-02 study for PF-06410293, a potential biosimilar to Humira 1 (adalimumab). Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_the_comparative_reflections_b538_02_study_for_pf_06410293_a_potential_biosimilar_to_humira_1_adalimumab. Published January 5, 2017. Accessed November 18, 2019.

Related Videos
Image credit:  Chanintorn.v | stock.adobe.com - PTSD Mental health concept, Psychologist sitting and touch hand young depressed asian man for encouragement near window with low light environment.Selective focus.
Image credit: сергей костюченко | stock.adobe.com - human head with brain
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.